Ignite Creation Date:
2024-05-06 @ 3:30 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04652765
Status:
TERMINATED
Last Update Posted:
2023-10-06
First Post:
2020-12-02
Brief Title:
Camostat With Bicalutamide for COVID-19
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Overview
Official Title:
COMBO Trial Camostat With Bicalutamide for COVID-19
Status:
TERMINATED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
PI Decision to closestop the study due to no new accrual
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COMBO
Brief Summary:
This will be a randomized open-label study to determine if camostat bicalutamide decreases the proportion of people with COVID-19 who require hospitalization compared to historical controls Patients with symptomatic COVID-19 diagnosed as outpatients will be randomized 11 stratified by gender to treatment with standard of care alone Arm 1 or with camostat and bicalutamide Arm 2
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IRB00254142 | OTHER | JHM IRB | None |